by Nicole Kuchinsky | Feb 29, 2016
Japan is making bold moves to redefine how cell therapies make it to market, and the world is taking notice. In late January, the Japan External Trade Organization (JETRO) collaborated with the Centre for Commercialization of Regenerative Medicine (CCRM) to host a...
by Mark Curtis | Feb 18, 2016
Welcome to your Cell Therapy Deal Review for the month of January. Things got off to a quick start with a number of cell-based immunotherapy companies announcing deals and research collaborations out of the gate, including a third acquisition by Juno. Juno...
by Nicole Kuchinsky | Feb 17, 2016
Cell therapy is not a new idea. Bone marrow transplantation—the first ever cell therapy—has been around since the 1950s. Over half a century of research has brought important advancements, yet this technology has struggled to make it to prime time. Understandably,...
by Mark Curtis | Dec 30, 2015
Welcome to your Cell Therapy Deal Review for the month of November. Astellas failed to achieve the majority share it needed to push through a takeover of Ocata Therapeutics valued at $379 million. ImmunoCellular Therapeutics announced a research agreement with MD...
by Mark Curtis | Dec 28, 2015
For those of you that missed ISCT’s recent webinar on manufacturing, needle-to-needle logistics and reimbursement, below is a brief re-cap of the key points on the reimbursement section that I provided. The presentation, including audio, should be available free on...
Comments